Early Access — free while we kick the tires
EdgarHawk

Pisano Wayne

Director

Director
2 filings analyzed · 2 companies · Latest 2026-02-13

Companies

Company Buys Sells Direction
ONCOLYTICS BIOTECH INC ONCY 1 0 Net buying
Altimmune, Inc. ALT 1 0 Net buying

Activity

February 2026
2026-02-13 ONCOLYTICS BIOTECH INC ONCY
high
Buy
30,000 shares
$25,338
Significance 7/10

Director Pisano buys 30,000 shares at $0.84; 8 other insiders bought within 14 days (cluster pattern)

Director Wayne Pisano purchased 30,000 shares at $0.84 on 2026-02-12, expanding his holdings by 6.5% to 492,414 shares total. The transaction occurred at a notably depressed price—$0.84 is 25.4% below the 52-week high of $1.42 and the current price of $1.06. Most significantly, this buy is part of a broader cluster pattern: 8 other insiders also purchased shares within the past 14 days, suggesting coordinated or independently arrived-at conviction at current levels. Pisano's cross-ticker track record shows an average 30-day return of +19.3% on his prior open-market buys, though that is not ONCY-specific. The cluster buy activity in a micro-cap company (market cap $84.8M) during a period of downward price movement warrants attention to what insiders may be signaling about valuation or near-term catalysts.

January 2026
2026-01-09 Altimmune, Inc. ALT
high
Buy
5,000 shares
$20,410
Significance 7/10

Director Wayne Pisano bought 5.0K shares of ALT at $4.08 as part of cluster buy pattern; company down -47.9% from 52-week high amid -95.3% revenue collapse and $-19.0M net loss.

Wayne Pisano, a director, purchased 5,000 shares at $4.08 on 2026-01-08, increasing his holdings by 58.8% to 13,498 shares. This purchase is notable because two other insiders also bought within the past 14 days, establishing a cluster buy pattern at a time when the stock has declined -47.9% from its 52-week high of $7.71 and is trading 26.0% below its 30-day average. The timing warrants investor attention given the company's deteriorating fundamentals: annual revenue has collapsed -95.3% year-over-year to $5,000 in the latest quarter, and the company posted a $-19.0M net loss over its most recent full fiscal year. The convergence of multiple insider purchases during a sharp drawdown, combined with severe revenue contraction and continued losses, creates a pattern investors should monitor closely to understand management's conviction around turnaround prospects or asset stabilization.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access